0001209191-21-015487.txt : 20210301 0001209191-21-015487.hdr.sgml : 20210301 20210301201707 ACCESSION NUMBER: 0001209191-21-015487 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210225 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shah Jatin CENTRAL INDEX KEY: 0001782186 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 21700693 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS, INC. STREET 2: 85 WELLS AVENUE CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-25 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001782186 Shah Jatin C/O KARYOPHARM THERAPEUTICS INC. 85 WELLS AVE. NEWTON MA 02459 0 1 0 0 EVP, Chief Medical Officer Common Stock 2021-02-25 4 A 0 22013 0.00 A 107691 D Stock Option (right to buy) 14.56 2021-02-25 4 A 0 59968 0.00 A 2031-02-24 Common Stock 59968 59968 D Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022. The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 33,887 RSUs previously reported in Table II, and 51,791 shares of common stock. This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Nancy Smith as Attorney-in-Fact for Jatin Shah 2021-03-01